Taselisib
1:55
Dr. Jhaveri Discusses the Potential of Immunotherapy in TNBC
Taselisib (GDC-0032) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor targeting phosphoinositide 3-kinase subtype PIK3CA.
Explore contextually related video stories in a new eye-catching way. Try Combster now!
